Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2535]

TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits...

TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk...

Insights into the spatial organisation and tumour microenvironment of primary testicular diffuse large B-cell lymphomas

Insights into the spatial organisation and tumour microenvironment of primary testicular diffuse large B-cell...

More men with prostate cancer are avoiding unnecessary surgery

More men with prostate cancer are avoiding unnecessary surgery

Nivolumab subcutaneous formulation given approval across multiple solid tumour types in the UK

Nivolumab subcutaneous formulation given approval across multiple solid tumour types in the UK

Prostate cancer discovery opens door to more tailored treatments

Prostate cancer discovery opens door to more tailored treatments

Liquid biopsy: A breakthrough technology in early cancer screening

Liquid biopsy: A breakthrough technology in early cancer screening

New discovery means IV medication could be taken orally for range of cancer, Alzheimer’s treatments

New discovery means IV medication could be taken orally for range of cancer, Alzheimer’s treatments

Simple spit test could finally turn the tide on prostate cancer

Simple spit test could finally turn the tide on prostate cancer

New breakthrough in cancer treatment: tiny vesicles help the immune system fight tumours

New breakthrough in cancer treatment: tiny vesicles help the immune system fight tumours

More from ecancer